Hamilton Lane Advisors’s Sage Therapeutics SAGE Stock Holding History

Hamilton Lane Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,460	Closed	-$2K	–	46
2018 Q1	$2K	Buy	+10,460	New	+$1.78M	1.59%	21
2016 Q3	–	Sell	-10,000	Closed	-$329K	–	70
2016 Q2	$329K	Buy	+10,000	New	+$333K	0.16%	51
2015 Q4	–	Sell	-159,303	Closed	-$6.74M	–	58
2015 Q3	$6.74M	Buy	159,303 +53,264	+50%	+$3.28M	3.32%	8
2015 Q2	$7.74M	Buy	+106,039	New	+$6.82M	2.92%	8

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hamilton Lane Advisors's SAGE Position: Q2 2018 in Review

Hamilton Lane Advisors sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 10,460 shares — an estimated $2K sold.

Hamilton Lane Advisors first reported a position in SAGE in Q2 2015 and held it in 4 quarters. The position peaked at $7.74M in Q2 2015. 268 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

Hamilton Lane Advisors reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
Hamilton Lane Advisors sold 10,460 Sage Therapeutics shares in Q2 2018, an estimated $2K.
Hamilton Lane Advisors first reported a position in Sage Therapeutics in Q2 2015 and held it in 4 quarters.
Hamilton Lane Advisors's Sage Therapeutics position peaked at $7.74M in Q2 2015.
268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Hamilton Lane Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.